Amycretin dosage

What Amycretin is

Amycretin (now also called zenagamtide) is an investigational single-molecule peptide that activates both GLP-1 and amylin receptors. It has been studied in subcutaneous and oral forms in phase 1 and phase 2 randomized trials, and phase 3 trials are registered. It is not an approved medicine, and this entry is for research information only.

Amycretin is a 68-amino-acid peptide with an average molecular weight of 7847 Da in which a GLP-1 receptor agonist portion and an amylin receptor agonist portion are connected by a linker of four glycine residues and one glutamic acid residue ^5. It is acylated with a C18 diacid-based side chain on the GLP-1 portion, which the developers state enables reversible albumin binding and a long systemic half-life ^5.… How it works →

Schedules by time period

study arms from registered trials, laid out week by week. Each bar is what the label states or what investigators gave participants; none is a recommendation.

Doses given in human trials

• In the subcutaneous phase 1b/2a study (NCT06064006), once-weekly amycretin was escalated from 0.3 mg to 60 mg over 36 weeks in Part B, and from 0.3 mg to maintenance doses of 20 mg (36 weeks), 5 mg (28 weeks) or 1.25 mg (20 weeks) in Parts C to E ^2.
• In the subcutaneous phase 2 trial in type 2 diabetes (NCT06542874), participants were randomized 6:1 to once-weekly amycretin or placebo and then to maintenance doses of 0.4, 1.5, 5, 10, 20 or 40 mg, starting at 0.2 mg with escalation every 4 weeks ^3.
• In the oral phase 2 trial in type 2 diabetes, participants were randomized 5:1 to once-daily oral amycretin or placebo with maintenance doses of 6, 25 or 50 mg, starting at 1.5 mg with escalation every 4 weeks ^4.
• In the oral first-in-human study (NCT05369390), single doses of 1 to 25 mg, 10-day multiple doses of 3 to 12 mg once daily, and 12-week fixed titration regimens up to two 50 mg tablets in a single daily dose were tested ^1.
• In a single-dose renal impairment study (NCT06559527), 42 adults (14 with normal renal function and 7 per renal impairment group, including end-stage renal disease) received one subcutaneous 0.3 mg dose with 4 weeks of follow-up ^11.
• The subcutaneous phase 2 trial in type 2 diabetes randomized 262 participants: 38 to 0.4 mg, 36 to 1.5 mg, 37 to 5 mg, 38 to 10 mg, 38 to 20 mg, 38 to 40 mg and 37 to placebo ^3.
• The oral phase 2 trial in type 2 diabetes randomized 186 participants: 54 to 6 mg, 51 to 25 mg, 51 to 50 mg and 30 to placebo ^4.
• In the subcutaneous phase 1b/2a study, 125 participants were randomized (101 to amycretin, 24 to placebo); Parts C to E sustained the maintenance dose for the last 12 weeks ^2.
• In the oral first-in-human study, 144 participants were enrolled (48 in Part A, 36 in Part B, 60 in Part C/D); the Part C/D fixed-titration groups went from 3 mg to 50 mg, from 6 mg to 2 × 50 mg, and from 3 mg to 2 × 25 mg once daily ^1.
• Phase 3 registrations under the name zenagamtide include AMAZE 7 (NCT07668414; once-weekly subcutaneous zenagamtide versus two semaglutide doses, primary endpoint at week 84, estimated 650), AMAZE 9 (NCT07720271; one of 5 oral once-daily dose levels versus placebo, week 76, estimated 950), AMBITION 7 (NCT07797335; once-weekly subcutaneous versus insulin glargine in type 2 diabetes, week 52, estimated 1,778) and AMBIENCE (NCT07861100; once-weekly subcutaneous with dose escalation versus placebo in atherosclerotic cardiovascular disease, estimated 8,500); dose amounts are not stated in the registry fields ^6,12,13,7.

How long did human studies run?

• Phase 2 subcutaneous and oral trials in type 2 diabetes: 3-week screening, 36-week intervention and 4-week follow-up ^3,4.
• Subcutaneous phase 1b/2a: 36 weeks (Part B, to 60 mg; Part C, to 20 mg), 28 weeks (Part D, 5 mg) and 20 weeks (Part E, 1.25 mg) ^2. Oral first-in-human: single dose with 21-day follow-up (Part A), 10 days of dosing (Part B), 12 weeks of dosing with 3-week follow-up (Part C/D) ^1.

Who was excluded from the studies

• Phase 2 (NCT06542874) registry exclusion criteria include any diabetes or obesity medication other than those allowed within 90 days before screening, uncontrolled and potentially unstable diabetic retinopathy or maculopathy, and known hypoglycaemic unawareness ^14.
• The phase 2 trials enrolled adults aged 18–75 years with type 2 diabetes (HbA1c 7.0–10.0%) on stable metformin with or without an SGLT2 inhibitor and BMI 23.0 to under 50.0 ^3,4; the phase 1 studies enrolled adults aged 18–55 years with BMI 25.0–39.9 depending on study part ^1,2.

Side effects reported in studies

• Treatment-emergent adverse events (any)
  89 of 144 participants (62%); gastrointestinal events made up 180 of 364 events (49%) · Oral first-in-human phase 1 ¹
• Gastrointestinal adverse events
  Most common event type (rates per group not given in the abstract) · Subcutaneous phase 1b/2a, overweight or obesity ²
• Serious adverse events
  21 of 261 participants (8%) overall, including 3 in the placebo group · Subcutaneous phase 2, type 2 diabetes ³
• Gastrointestinal adverse events
  26% (6 mg), 41% (25 mg), 47% (50 mg) versus 23% placebo · Oral phase 2, type 2 diabetes ⁴
• Serious adverse events
  7 of 186 participants (4%) receiving oral amycretin; none with placebo · Oral phase 2, type 2 diabetes ⁴

Amycretin draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

2 mg5 mg10 mg

2 · Water added

1 mL2 mL3 mL5 mL

3 · Amount per draw

mcgmg

4 · Syringe

30u50u100u

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

• Lyophilized vial
  Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
• Sterile diluent
  The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
• Graduated syringes
  Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
• Alcohol prep pads
  For wiping vial stoppers before each puncture.
• Nitrile gloves
  Clean gloves for aseptic handling.
• Sharps container
  Puncture-resistant container for used needles.

Storage

Storage conditions for research material are set by the supplier's documentation; lyophilized peptides are generally sensitive to heat, light and moisture.

• Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
• Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
• Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent

The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.

Shook the vial and it foamed

Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.

The solution is cloudy or has particles

Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.

The powder cake looks melted or shrunken before reconstitution

This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.

Liquid sprayed back when the needle was removed

Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status

Investigational. The 2026 phase 2 reports describe zenagamtide (formerly amycretin) as a novel agent ^3,4, phase 3 trials are registered under the zenagamtide name ^6,7, and an openFDA query of Drugs@FDA on 22 October 2026 returned no application record for either name ^8.

United States (FDA)

Amycretin (zenagamtide) is investigational; openFDA queries of Drugs@FDA application data on 22 October 2026 returned no application record under either name ^8, and phase 3 trials were registered ^6,7.

Sport (WADA)

Amycretin is not named in the 2026 Prohibited List text reviewed. The list's S0 class covers pharmacological substances not addressed elsewhere that have no current approval by any governmental regulatory health authority, including drugs in clinical development; athletes should consult WADA directly ^10.

Status varies by country and changes over time. How we describe regulatory status.

Amycretin compared with related compounds

Frequently asked questions

References

1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial Lancet. 2025
2. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study Lancet. 2025
3. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial Lancet. 2026
4. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial Lancet. 2026
5. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats EBioMedicine. 2025
6. AMAZE 7: zenagamtide compared with semaglutide in people with excess body weight (NCT07668414) ClinicalTrials.gov. 2026
7. AMBIENCE: zenagamtide compared with placebo in people with established atherosclerotic cardiovascular disease and overweight or obesity (NCT07861100) ClinicalTrials.gov. 2026
8. Drugs@FDA application data queried through openFDA for amycretin and zenagamtide (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
9. PubChem substance record for amycretin (SID 530736542) PubChem. 2026
10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
11. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide Diabetes Obes Metab. 2026
12. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight (NCT07720271) ClinicalTrials.gov. 2026
13. AMBITION 7: zenagamtide compared to insulin glargine in people with type 2 diabetes and increased cardiovascular risk (NCT07797335) ClinicalTrials.gov. 2026
14. Zenagamtide (amycretin) phase 2 dose-finding trial in type 2 diabetes, registry record (NCT06542874) ClinicalTrials.gov. 2024